North Immunology to go public via reverse merger with Aethlon Medical

Key points

• North Immunology, founded by analyst Mohit Gupta and incubated by ADAR1 Capital, will merge with Aethlon Medical to go public.
• The lead drug candidate, NOR-101, is a bispecific antibody targeting IL-13 and IL-18 for atopic dermatitis, with a 42-day half-life in preclinical studies.
• The merger is funded by an $180 million private placement from Bain Capital Life Sciences, Janus Henderson Investors, and Deep Track Capital.
• Legacy Aethlon shareholders will own 4.75% of the combined company, while North Immunology and new investors hold 95.25%.
• Clinical trials for NOR-101 are scheduled to begin in Q1 2027, with Phase 2b data expected in 2028.
• Aethlon’s Hemopurifier business will be separated, with legacy shareholders receiving contingent value rights from any future sale proceeds.

Background

This move follows a trend of biotech firms seeking alternative paths to public markets, such as reverse mergers, to accelerate clinical development. The broader biotech sector has seen increased activity in immunology and dermatology, with companies like Sanofi and Regeneron dominating the atopic dermatitis market with IL-13 inhibitors. The merger also reflects the growing influence of hedge funds like ADAR1 Capital in incubating and launching new biotech ventures, a strategy that has gained traction in recent years.

How outlets are covering it

STAT emphasizes the origin of North Immunology as a venture incubated by ADAR1 Capital, highlighting the role of hedge funds in creating new biotech companies. Fierce Biotech focuses on the clinical pipeline, particularly the bispecific antibody NOR-101, and the strategic rationale for targeting both type 2 and non-type 2 inflammation. TechStock² provides a financial analysis, noting that Aethlon’s stock surged 467% on the announcement but that legacy shareholders will hold only a 4.75% stake in the combined company, which is valued at $346.5 million. TechStock² also cautions that the merger’s success depends on several regulatory and financial conditions, including the completion of the private placement and antitrust clearance.

Why it matters

The merger signals a shift in how biotech companies access public markets, with reverse mergers becoming a viable alternative to traditional IPOs. The focus on bispecific antibodies for atopic dermatitis reflects the growing demand for therapies that address multiple inflammatory pathways, potentially offering better outcomes than current monoclonal antibodies. The involvement of major investors like Bain Capital Life Sciences and Janus Henderson Investors underscores the confidence in North Immunology’s pipeline, while the separation of Aethlon’s Hemopurifier business highlights the strategic focus on the most promising assets.

What to watch

The next steps include the completion of the private placement, regulatory approvals, and the launch of Phase 1 trials for NOR-101 in Q1 2027. Investors will closely watch the S-4 filing for details on the exchange ratio and pro forma capitalization. The success of the merger will depend on the clinical performance of NOR-101 and the ability to secure additional funding if needed.